FLUTICASONE
Recurrent Primitive Neuroectodermal Tumor
Mayo ClinicSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Primitive Neuroectodermal Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sargramostim Mayo Clinic | Phase 1 | CC |
Wild-Type Reovirus Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
FLUTICASONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →